Review of Alterations in Endothelial Nitric Oxide Production in Diabetes Protective Role of Arginine on Endothelial Dysfunction
Galen M. Pieper N itric oxide release from the endothelium plays an important role in regulation of vascular tone, 1 inhibition of both platelet and leukocyte aggregation and adhesion, 1,2 and inhibition of cell proliferation. 3 These properties suggest that the level of NO production by the endothelium may play a pivotal role in the regulation of vascular disease. Analysis using mass spectrometry has revealed that NO is produced by NOS from the terminal guanidino nitrogen of the precursor amino acid L-arginine. 4 Thus, utilization of L-arginine and conversion to NO may establish a regulatory site in the development of endothelial dysfunction.
Endothelial dysfunction is characterized by defective endothelium-dependent relaxation, and some reviews regarding endothelial dysfunction in diabetes have been published. [5] [6] [7] [8] These reviews have focused on factors that might contribute to defective relaxation, some of which will not be addressed in detail in this review. The purpose of the present review is to summarize evidence that specifically supports either decreased NO production by diabetic vascular endothelium and/or impaired NO-mediated endothelium-dependent relaxation. Second, this review provides reasonable alternatives to explain some of the controversies in this research area. Third, since there is growing evidence that arginine appears to have some benefits for diabetes-associated abnormalities, this review summarizes the current state of knowledge of effects of acute and chronic administration of L-arginine on diabetesinduced endothelial dysfunction and discusses potential NOdependent and -independent mechanisms whereby therapeutic intervention with L-arginine might benefit the diabetic endothelium.
Impaired Endothelium-Dependent Relaxation Experimental Diabetes Mellitus
Decreases in endothelium-dependent relaxation are a common feature in both conduit 9 -20 and resistance [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] arteries of chemically induced experimental diabetic animals (including rats, mice, rabbits, hamsters, and dogs). In two genetic models of IDDM, similar impaired relaxation has been documented in aorta [31] [32] [33] and mesenteric arteries 34, 35 of diabetes-prone BB/Wor or BB/E rats and in aorta 36 and mesenteric arteries 37 of the diabetes-prone WBN/Kob rat. Almost without exception, studies that have shown impaired endothelium-dependent relaxation have found normal relaxation to nitrovasodilators. These agents relax vascular smooth muscle by activating guanylate cyclase but, unlike NO, do not require the presence of the endothelium. Thus, the intrinsic property to activate vascular smooth muscle guanylate cyclase appears not to be altered by experimental diabetes.
Studies in experimental models of NIDDM are few and controversial. In the obese Zucker rat, no alteration in endothelium-dependent relaxation has been observed in intestinal microvessels, 38 whereas increased reactivity has been observed in aorta. 39, 40 In contrast, decreased endotheliumdependent relaxation to acetylcholine but not to A23187 was seen in aorta in male (but not female) JCR:LA-corpulent rats. 41 Little is known regarding the nature of endothelial dysfunction in these models.
Conclusion. Collectively, these studies suggest that endothelial dysfunction (1) is not unique to chemically induced experimental models of IDDM, (2) is found in both conduit and resistance arteries, and (3) cannot be explained by an intrinsic change in reactivity to NO or guanylate cyclase reactivity. Studies conducted in experimental models of NIDDM are few and provide no clear consensus regarding this issue.
Human Diabetes Mellitus
The first evidence of endothelial dysfunction in humans was reported in penile corpura cavernosa of IDDM and NIDDM patients. 42 Impaired endothelium-dependent relaxation of conduit blood vessels has been confirmed in both IDDM [43] [44] [45] [46] [47] and NIDDM 43,48 -53 patients evaluated in vivo or in isolated arteries in vitro. 45, 51 A few studies in IDDM 54 -56 or NIDDM patients 57 report no defect. One study of resistance vessels derived from NIDDM patients and evaluated in vitro showed enhanced reactivity to acetylcholine. 58 Evaluation of the latter study is compromised because the control patients selected exhibited arterial occlusive disease, hypercholesterolemia, Alternatively, one of these studies noted no difference in reactivity to nitroglycerin after correction for differences in baseline diameter. 61 Furthermore, diabetic patients with microalbuminuria exhibited impaired dilation to isosorbide dinitrate, while in diabetic patients without microalbuminuria, dilation was unaltered. 66 In this regard, dilation in response to carbachol was normal in diabetic patients but was blunted by an NOS inhibitor in both control and diabetic patients without microalbuminuria but not in diabetic patients with microalbuminuria. 56 Thus, there may be variable mechanisms of impaired vascular reactivity to nitrovasodilators among different diabetic patient subpopulations.
There are several concerns regarding critical evaluation of the data obtained in diabetic patients. Whereas some investigators have carefully eliminated patients taking medications (eg, vasoactive and cardiovascular drugs) and have limited intake of caffeine or alcohol before evaluation, other investigators have either not provided information regarding patient selection or have ignored these potential influences. Some studies have included patients with histories of smoking (an independent risk factor for endothelial dysfunction) or have only limited smoking just before the study.
Most studies have used a mixed-gender patient population. Thus, the influence of gender-related differences has not been isolated. Indeed, it is widely known that diabetes-induced complications are enhanced in the female population. A recent study has revealed diminished reactive hyperemia (an endothelium-related phenomenon) in young female IDDM patients compared with age-matched male subjects. 67 Furthermore, inclusion of postpuberty female patients using oral contraceptive agents has been acknowledged in some studies, 61, 62 but the significance of inclusion of this subpopulation has not been addressed. In studies using male subjects only, endothelial function was either impaired 46 -47,49 -50 or unchanged. 54, 55, 57 In studies of vascular reactivity using NIDDM patients, it was acknowledged that many subjects were receiving hypoglycemic drugs or insulin at the time of evaluation. [47] [48] [49] 51, 52, 64, 68 Oral hypoglycemic agents such as glibenclamide can impair dilation mediated by NO-mediated K ATP channel activation. 69 Thus, the effects of this medication on NO-mediated relaxation have not been uniformly excluded. One study showed no difference in endothelium-dependent relaxation between patients taking oral hypoglycemic agents and those controlling the disease by diet alone. 48 In one study in which hypoglycemic medication was removed for a finite period before evaluation, there was diminished reactivity to acetylcholine but not to nitroprusside. 53 Endothelial function in patients has been determined in vivo using either strain-gauge plethysmography or Doppler techniques, predominately in brachial/forearm protocols. A few have evaluated dilation in the femoral artery 53, 63, 64 or coronary arteries. 43 While there is important value in examining reactivity in vivo under ambient conditions, there are several significant complicating factors that make the in vivo delineation of mechanisms difficult. For example, one investigator found that endothelial dysfunction correlated with serum triglyceride and lower HDL cholesterol levels. 50 Furthermore, ambient glycated proteins may diminish endothelium-dependent relaxation studied in vitro, 70, 71 although a recent in vitro study in canine conduit and resistance artery preparations could not confirm this effect. 72 Conclusion. Patient selection and screening have the potential to explain differences in findings obtained in clinical studies. The potential influence of gender, presence of microalbuminuria, and use of medications, including oral contraceptives and hypoglycemic agents, need to be rigorously evaluated in clinical studies. Also, the influence of ambient glucose concentration, glycated proteins, and lipids on endothelial function needs to be considered in clinical evaluations.
Confounding Effects of Ambient Glucose Concentration
Ambient plasma glucose concentration could be a confounding factor in vivo as well. Some studies in experimental animal models have noted acute vasodilation (ie, seconds to minutes) in response to concurrent elevation in glucose concentration. [73] [74] [75] In contrast, short-term exposure (ie, minutes to several hours) to elevated glucose concentrations in vitro or topical application in situ impairs basal NO tone 76 and agonist-stimulated endothelium-dependent relaxation. [77] [78] [79] [80] [81] Interestingly, 24-hour infusion of glucose in normal subjects did not impair relaxation. 82 Because multiple agonists were used in the latter study, the significance of masking by crossover effects of individual drugs cannot be excluded in the interpretation of this data. In contrast, evaluation during an acute bolus of glucose administration (ie, during a glucose tolerance test) revealed decreased endothelium-dependent relaxation. 87, 88 To circumvent this potential limitation, one study using the euglycemic insulin clamp protocol 46 revealed that endothelial function was diminished. Also, analysis in vitro of human gluteal resistance arteries under normoglycemic conditions also revealed diminished endothelium-dependent relaxation. 45 The latter study suggested an intrinsic defect in endotheliumdependent relaxation in IDDM that is independent of direct effects of concurrent ambient glucose concentrations in vivo. In contrast, another study showed that relaxation to carbachol was unchanged in IDDM patients under euglycemic conditions produced by insulin infusions. 56 Interestingly, a defect in NO synthesis was still suggested in patients with microalbuminuria based on the lack of response to N G -monomethyl-Larginine (L-NMMA).
Conclusion. The confounding effects of ambient glucose concentration on endothelial function in studies performed in patients and in experimental diabetes in vivo should be taken into account when glucose concentration is not normalized. Unfortunately, controlling for this contingency may be difficult, particularly in clinical studies. Clearly, there are important direct stimulatory and inhibitory effects of elevated glucose concentration on vascular reactivity that may be manifested at different times subsequent to rises in glucose concentration.
Paradoxical Findings on Endothelial Function: Role of Disease Duration
Few studies have examined the temporal nature of the onset of endothelial dysfunction in experimental diabetes. Most have shown a progressive worsening of dysfunction that appears to plateau at some finite point in time. Dysfunction has been reported at as early as 1 week of diabetes in rat intestinal arterioles, 30 after 2 weeks in hindquarters but not in mesenteric or renal arteries, 89 after 3 weeks in cremaster muscle arterioles, 90 after 4 to 6 weeks in mesenteric arterioles, 25, 91 and after 4 weeks in aorta. 70 Thus, lack of endothelial dysfunction of diabetic rat aorta at 2 to 3 weeks of disease 92 could be explained by the short period of time studied. It is important to note that the onset of endothelial dysfunction may vary widely among individual vascular beds and/or the severity of the diabetic model used in any given study.
Interestingly, there are paradoxical reports of normal endothelium-dependent relaxation in aorta after Ͼ12 weeks of diabetes [93] [94] [95] and after 15 to 17 weeks of diabetes in perfused mesenteric preparations. 96 The reasons for these disparate observations compared with other findings are unclear. Potential explanations might include the use of helical strips, 93 diabetes-induced hypersensitivity to phenylephrine and evaluation only in indomethacin-treated preparations, 94 use of a low dose of streptozotocin, 94 or the potential influence of masking by crossover effects due to multiple drug challenges. 95 There is clinical and experimental evidence showing augmented blood flow at early stages of diabetes. 97 It is not at all clear whether this increased blood flow reflects increased NO-specific endothelium-dependent dilation. One possibility that needs to be examined is whether the diabetes-induced decreases in 2,3-diphosphoglyceric acid levels in red blood cells, 98 which regulate oxygen release from hemoglobin, lead to a "hypoxic-like" environment. 99 Decreases in tissue ATP concentration could result in increased blood flow due to hypoxic-induced dilation in compensation for reduced oxygen delivery to tissue. Indeed, myocardial ATP concentration is reduced in diabetes but is rapidly replenished within minutes of perfusion in vitro with oxygenated blood-free salt solutions. 100 Furthermore, in situ analysis using microelectrodes reveals diminished oxygen tension in aorta of alloxandiabetic rabbits. 101 Thus, increase in tissue blood flow at the early stages of diabetes may be due to hypoxic vasodilation. Alternatively, increased blood flow may be a direct response to acute or short-term hyperglycemia, since coronary blood flow is increased with glucose infusions in isolated hearts in the presence of indomethacin. 75 At least one study has noted augmented endotheliumdependent relaxation in indomethacin-treated rat renal arteries at an early stage of diabetes. 102 Because endotheliumdependent relaxation is reduced in renal arteries of diabetic rats of longer disease duration, 103 this observation raises the possibility that diabetes induces biphasic effects on endothelium-dependent relaxation. Thus, an early increase in blood flow may be followed by a transition state to impaired relaxation. In support of this hypothesis, one study noted an increase in endothelium-dependent relaxation of mesenteric arteries to both acetylcholine and bradykinin at 6 weeks of diabetes that reverts back to normal after 12 weeks. 104 This enhanced relaxation could not be accounted for by intrinsic changes in smooth muscle reactivity because responses to sodium nitroprusside were normal.
It remains to be resolved in temporal studies using various preparations whether the enhanced endothelium-dependent relaxation at early stages might be due to diabetes-induced increases in synthesis of vasodilator prostaglandins, EDHF, or NO, or a combination of any of these endothelium-derived factors. In this regard, studies conducted in mesenteric 104 and renal 102 arteries in the presence of indomethacin suggest that vasoactive prostanoids do not contribute to enhanced endothelium-dependent relaxation, leaving EDHF and NO as candidate factors.
Conclusion. Time of evaluation after onset of disease may be critical to demonstrating endothelial dysfunction. Indeed, evidence exists for enhanced endothelial function at early stages followed by dysfunction at later stages. Whether these opposing actions are causally linked is not yet known. Further studies are warranted to understand this temporal dichotomy.
Role of Prostanoids in EndotheliumDependent Dilation in Diabetes
Impaired endothelium-dependent relaxation in diabetes cannot always be assumed to be mediated by a reduction in NO activity or synthesis, since some vasodilators also release prostaglandins. Changes in prostaglandin synthesis may alter NO production or reactivity to NO. Because diabetes alters the reactivity to prostanoids and may either increase or decrease prostacyclin production depending on the artery chosen, 105 this issue needs to be resolved, especially at various stages of disease and in individual blood vessel preparations.
Simultaneous enhancement and release of vasoconstrictor prostaglandins may explain some instances of impaired endothelium-dependent relaxation. Indeed, in aorta, pial artery, and mesenteric artery, relaxation is either normal 94 or is normalized in the presence of indomethacin or thromboxane receptor antagonists. 13, 21, 103, 106 In contrast, endothelial function was normal in coronary arteries of alloxan-diabetic dogs, but dysfunction was unmasked in the presence of inhibitors of cyclooxygenase, 11, 107 suggesting enhanced compensatory increases in vasodilator prostanoid release. Furthermore, increases in production of the vasodilator prostacyclin have been reported in perfused mesenteric beds of 3-week diabetic rats. 108 While not directly examined, this might provide an alternative explanation for one of the early reports showing augmented relaxation to the agonist histamine in mesenteric arteries of diabetic rats 109 or the observation of normal relaxation seen in perfused mesenteric beds of long-term diabetic rats. 94 In contrast, this may not be adequate to explain the increased endothelium-dependent relaxation seen in perfused kidney at early stages of disease, since this increase was seen in indomethacin-treated preparations. 102 One investigator has shown that thromboxane receptor antagonism does not alter relaxation in basilar artery 110 but restores relaxation of pial arteries taken from the streptozotocin-diabetic rat model. 21 These observations suggest important regional differences, although one cannot exclude the possible contribution of the superimposition of the variable in the duration of disease, which was 4 to 5 months in the basilar artery study versus 2.5 to 3.5 months for the pial artery study. In another model of alloxan-diabetic dogs in which duration of disease was held constant, inclusion of indomethacin or ibuprofen unmasked a defect of endothelium-dependent relaxation in coronary artery 11 but not renal artery. 111 Collectively, these studies suggest important regional differences in the mechanism of endothelial dysfunction.
Many studies using either rat conduit arteries 9,14,16 -18,112-114 or rat resistance arteries 25, 26, 91, 103, [115] [116] [117] have indicated no improvement in endothelial function after evaluation under conditions of cyclooxygenase blockade or thromboxane receptor antagonism. Similar interventions have failed to modify defective relaxation in aorta of the genetic diabetic BB rat 33 and in coronary arteries of alloxan-diabetic dogs. 20 The effect of prostanoids on endothelial function in human diabetes has not been routinely evaluated. Prior treatment with indomethacin in vitro normalized impaired endothelium-dependent relaxation in cutaneous arteries of gestational diabetes. 118 In contrast, in one human study in which all patients received aspirin before evaluation, 44 the authors concluded that exogenous prostanoid synthesis cannot account for the endothelial dysfunction in IDDM.
Conclusion. There exist some potentially important regional differences in the role of prostanoids in contributing to altered endothelium-dependent dilation in diabetes mellitus, although this cannot be easily predicted among various conduit versus resistance vessels. Nevertheless, there is clear and ample evidence to suggest that alterations in prostanoid production may not always account for and/or may not be obligatory for impaired endothelial function in diabetes.
NO-Dependent or -Independent Endothelial Dysfunction
Implicit in all of these studies is the assumption that endothelium-dependent relaxation in both control and diabetic blood vessels is exclusively mediated via NO. This assumption is hazardous because endothelium-dependent relaxation to certain agonists and in certain arteries appears to be mediated in part by vasodilator prostanoids or by an EDHF. 119 The entity of EDHF is not known with complete certainty, but at least one EDHF is believed to be an epoxide of arachidonic acid that is formed by a cytochrome P450 -derived monooxygenase. 120 EDHF appears to activate K ϩ channels, especially calciumactivated K ϩ channels. 119 The contribution of K ATP channels to relaxation in diabetes is uncertain and should also be considered. A few studies have noted diminished responses to K ATP channel openers in diabetic rat aorta 15, 121, 122 and basilar artery. 123 One study in the aorta of WBN/Kob rat showed no alteration in relaxation to the K ATP channel agonist cromakalim. 124 In contrast, others have observed a paradoxically enhanced response in dog coronaries to aprikalim, albeit in short-term diabetes. 125 In normal arteries, it is generally believed that the component of EDHF versus NO that contributes to total relaxation increases with decreasing vessel size. The observation that diabetes-induced endothelial dysfunction can occur in both conduit and resistance arteries despite cyclooxygenase blockade suggests that this dysfunction could be explained by defects in EDHF or by deficits in NO synthesis unrelated to or in addition to changes in EDHF or prostanoids.
Two studies in rat aorta reveal that endothelial dysfunction persists despite pretreatment with TEA (to inhibit calciumactivated K ϩ channels), suggesting that defects in EDHF may not be operative. 126, 127 Alternatively, a recent study in perfused kidney indicates that endothelium-dependent relaxation in control kidney arises from both NO and EDHF, whereas relaxation in diabetic kidney arises from NO, EDHF, and prostanoids. 128 Few studies have examined perturbations in membrane polarization in diabetic vascular tissue. Membrane hyperpolarization is known to occur in gastric gland of 2-to 3-day diabetic rabbits 129 and in endothelial cells from human sub-jects with gestational diabetes. 130 One study showed normal resting membrane potential but diminished hyperpolarization in the response of diabetic mesenteric artery to acetylcholine 131 despite unaltered hyperpolarization in response to the K ϩ channel agonist pinacidil. This report conducted in the presence of NOS and cyclooxygenase inhibitors suggested diminished endothelium-dependent, TEA-sensitive hyperpolarization and relaxation.
Conclusion. Endothelial dysfunction in some cases of diabetes and in certain blood vessel types may arise from deficits in EDHF, but it is also clear that endothelial dysfunction can also occur despite blockade of EDHF and prostanoid synthesis and action, suggesting a role for deficits of endothelium-derived NO. It is possible that previous studies may need to be carefully reevaluated, since alternative compensatory pathways including cytochrome P450 -derived EDHF may be activated or inactivated, which could mask impaired endothelium-dependent relaxation or compensate for defective NO synthesis. It should be emphasized that parallel compensatory pathways may be important at certain stages but perhaps not at all stages of the disease.
Evidence Supporting Altered NO Production From Diabetic Endothelium Functional Studies in the Presence of SOD
NO activity is known to be reduced by chemical interaction and destruction by superoxide anion radicals. Several investigators have noted improved relaxation after acute incubation with SOD. 14, 25, 26, 33, 77, 117, 132 This issue has been discussed in detail in a previous review. 7 Nevertheless, these studies are consistent with increased destruction of NO and decreased bioactivity of NO in diabetes, but they do not give adequate direct information regarding perturbations in NO production.
Currently, there have been no studies that have directly determined NO synthesis or release from diabetic endothelium. Only one laboratory has examined intraluminal release of NO activity from perfused diabetic rat aorta donor segments using the bioassay technique. 133 Accordingly, luminally released basal NO activity in perfused diabetic rat aorta was normal, but addition of SOD caused a larger incremental increase in relaxation of the bioassay detector when the diabetic donor segment was used. This suggested the increased release of superoxide anion radicals from diabetic rat endothelium. In contrast, acetylcholine-stimulated endothelium-derived relaxing factor/NO bioactivity from perfused diabetic rat aorta was diminished but also normalized by perfusion with SOD. 114 Conclusion. Several studies support the concept that IDDM decreases NO bioactivity. This may be due in part to enhanced destruction of NO by increased superoxide synthesis.
Indirect Evidence Using Guanylate Cyclase Inhibitors
Use of inhibitors of NOS or NO reactivity (eg, hemoglobin or methylene blue) has given indirect information regarding the contribution of NO to basal tone and agonist-induced relaxation in control versus diseased blood vessels. Many studies that have used removal of endothelium or NOS inhibitors or hemoglobin, which increase the precontracted tone of arteries, reveal decreased basal NO activity in both diabetic conduit 16,94,134 -140 and resistance 24,25,35,132,140 -145 arteries under both in vitro and in vivo conditions. Two studies noted enhanced contraction to methylene blue in control versus diabetic rat aorta ring preparations, suggesting diminished basal NO in diabetic arteries. 16, 133 The use of methylene blue alone is inadequate because of the known effects of methylene blue to stimulate superoxide anion radical or inhibit NOS. 146, 147 One study using a new highly selective inhibitor of guanylate cyclase, ODQ, revealed that ODQ completely inhibits acetylcholine-induced relaxation in control rat aorta and inhibits relaxation in diabetic rat aorta by 80%. 148 This suggests that almost all of the relaxation in both groups is mediated by cGMP activation, implicating NO as the EDRF. Also, the small ODQ-resistant component of relaxation in diabetic rat aorta leaves open the possibility of some other unknown factor that appears unrelated to vasodilator prostanoids, H 2 O 2 , or a TEA-sensitive EDHF.
Conclusion. Overall, these studies suggest diminished basal NO production in diabetes.
Evidence Using NO Trapping Agents
Basal NO activity in rat aorta has also been assessed using either a small-molecular-weight, iron-thiol-based NO scavenger 149 or a nitronyl nitroxide trapping agent. 148 These agents are different in that they do not alter NOS activity but react with NO after its release. These probes were effective in scavenging all basal NO based on similar tension responses after removal of endothelium or by using NOS inhibitors and confirm a smaller basal NO activity in diabetic rat aorta. This NO scavenger-sensitive basal NO activity was augmented by L-arginine in diabetic but not control aorta. 149 In contrast, despite nearly complete inhibition of acetylcholine-mediated relaxation by both control and diabetic rat aorta by NOS inhibitors, use of a nitronyl nitroxide revealed an NO scavenger-resistant component of agonist-stimulated relaxation that is greater in diabetic than control arteries. 148 This resistant component of endothelium-dependent relaxation was sensitive to NOS inhibitor but was insensitive to indomethacin, TEA, or catalase, suggesting that this additional EDRF is likely not EDHF, prostanoids, or H 2 O 2 . A significant portion of this resistant component was eliminated using ODQ, suggesting that this EDRF is an activator of guanylate cyclase. Current research continues to attempt to identify whether diabetic arteries produce an additional vasoactive product that is derived from the NOS reaction but that may not necessarily be a free NO radical.
Measurement of NO by cGMP Generation
Information regarding potential deficits in NO synthesis have also been derived from measurement of cGMP in vascular tissue. Although one study showed no significant alteration in basal and acetylcholine-stimulated cGMP in alloxan-diabetic aorta, 150 an earlier study in the same animal model showed that diabetes decreased both basal and acetylcholine-stimulated cGMP. 19 The latter study differed only in that duration of disease was longer and that a preconstrictor agonist was used in the assays. Similar decreases in acetylcholine-stimulated cGMP production have been observed in rat and rabbit aorta and mesenteric arteries, 12, 19, 151, 152 in canine coronary arteries, 107 and in isolated rat glomeruli. 153, 154 In contrast, cGMP in response to nitroprusside was diminished in isolated glomeruli from diabetic rats. 153 In the presence of the phosphodiesterase inhibitor IBMX and after stimulation with nitroprusside, cGMP production was not altered by diabetes in rat aorta 152 or glomeruli. 154 There is no apparent intrinsic change in either guanylate cyclase or phosphodiesterase activity of vascular smooth muscle to account for defective cGMP production in diabetic blood vessels. The evidence suggests decreased basal and agonist-stimulated NO bioactivity in experimental diabetes mellitus.
Measurement of NO or NO By-products
To our knowledge, there has been no direct measurement of NO from diabetic arteries using NO electrodes or an NO analyzer. According to indirect measurements of the NObased by-products nitrate and nitrite, levels of either nitrite or nitrateϩnitrite in urine of diabetic rats were increased. 26, 142, [155] [156] [157] [158] [159] [160] [161] Streptozotocin, the agent frequently used to produce experimental diabetes, is also a known NO donor compound. 162 This property could potentially contribute to enhanced urinary nitrate/nitrite levels at early stages of diabetes. This limitation is likely not a problem for samples taken several weeks after the administration of streptozotocin. Furthermore, the increased urinary nitrateϩnitrite might simply be secondary to hyperfiltration. Although some studies have controlled for nitrate/nitrite derived from food during diabetes-induced hyperphagia, most have not controlled for variation in nitrate consumption derived from drinking water due to diabetes-induced increases in water consumption or for NO released simply because of the mechanical stimuli of increased renal blood flow and filtration due to excess volume disposal as a consequence of diabetes. Thus, the relationship between urinary nitrate/nitrite concentration and vascular endothelium production of NO must be understood in the context of these significant limitations.
Some studies have reported increases in both urine and plasma nitrateϩnitrite concentration in diabetic animals. [157] [158] [159] 161 In contrast, levels of plasma nitrate 163 and of cGMP 164 were normal in diabetic patients. Although nitrate levels were normal, 163 exhaled NO level was decreased by 30% but did not reach statistical significance because of the small sample size. Infusion of L-NMMA caused a greater decrease in exhaled NO in healthy versus diabetic patients, although nitrate levels did not change, suggesting decreased NO synthesis. Nevertheless, changes in plasma NO do not provide concrete information regarding the location and source of NO production.
Conclusion. Measurement of nitrate/nitrite in plasma and urine in experimental diabetes supports increased NO production. Because the source of this increased nitrate and nitrite is not easily ascertained, conclusions regarding endothelial cell NO production based on these measures alone are hazardous and must be taken as confirmation of other derived parameters.
Measurement of NOS Protein, mRNA, or Activity
There is little information available concerning measurement of endothelial cell NOS protein content or mRNA in diabetes mellitus. Diaphorase staining and immunohistochemical staining suggest reduced NOS activity in sympathetic autonomic ganglia 165 and macula densa 166 of experimental diabetic rats. Another study revealed a decrease in mRNA and content of neuronal NOS (nNOS) in diabetic penile tissue. 167 Interestingly, one study in diabetic rat heart homogenates noted increased NOS activity (believed to be largely constitutive NOS [cNOS]) determined by arginine to citrulline conversion along with increased cNOS mRNA and protein. 26 There was no detectable inducible NOS (iNOS), although induction of iNOS was previously reported in placenta of gestational diabetic patients. 168 In rat renal tissue at 1 week of diabetes, mRNA and protein for cNOS, iNOS, and nNOS were all increased in cortex but unchanged in medulla. 169 Consistent with these reports are increases in mRNA and/or protein for cNOS after culture with elevated glucose concentrations in bovine aortic endothelial cells for 24 hours (G.M.P., unpublished observations, 1997) and in human aortic endothelial cells after 5 days. 170 In contrast, longer-term culture under high glucose conditions of human umbilical vein endothelial cells revealed no alteration in either mRNA or protein for cNOS. 171 This suggests either heterogeneity in the response of different endothelial cells or glucose concentration-dependent and/or exposure time-dependent differences.
In the diabetic heart study, the finding that normal or enhanced NOS activity occurs under acellular conditions despite concomitant decreases in endothelium-dependent relaxation indicates no intrinsic defect in NOS activity. This is consistent with elevations in mRNA for endothelial cellderived NOS despite decreased NO production in endothelial cells cultured with elevated glucose for 24 hours. 86 In isolated endothelial cells from diabetic BB rat, 172 nitrate/ nitrite production in culture was diminished, as well as citrulline production from arginine, and occurred without changes in arginine uptake. The latter suggests no defect in the y ϩ transporter function in these cells. In contrast, alloxan diabetes enhanced cGMP production and increased both V max and K m for arginine in gastric glands. 129 The significance of these observations to arginine content in vascular disease is unknown; however, it should be noted that these studies were conducted just 2 to 3 days after diabetes induction. Similar actions have been found by this same group in human fetal endothelial cells in gestational diabetes. 130 Conclusion. There are too few measurements of NOS activity, mRNA, and protein in the literature to formulate a consensus. There is some evidence of increased mRNA and protein despite impaired endothelial function. These observations suggest that NO synthesis might be regulated by factors present in the intact cell under conditions (eg, substrate provision or cofactor concentration) that may not be optimal for NOS enzyme activity (see "Discussion").
Arginine Deficiency and/or Substrate Utilization by NOS
Plasma arginine concentration is decreased in diabetic rats 26, 138, 159, 173, 174 and in some human diabetic patients. 175, 176 In contrast, some reports involving a small number of patients have reported normal arginine levels. 177, 178 In streptozotocininduced diabetes, decreases in plasma arginine and endothelial dysfunction are corrected by subsequent transplantation of either whole pancreas 179 or pancreatic islets. 174 The reasons for decreased plasma arginine are unclear. One study showed that plasma arginine was decreased at 14 days. 159 This was associated with a larger excretion of arginine with increases in nitrate/nitrite and cGMP, suggesting that lower plasma arginine results from increased renal NO production and/or increased elimination of arginine. Tissue levels of arginine might be decreased as the plasma arginine concentration in diabetic rats is near the K m for arginine transport into endothelial cells and the K m does not appear to change, at least in certain tissue and during early stages of diabetes. 129 There is a paucity of information regarding arginine content in diabetic tissue. Despite increased arginine content in gastric glands of 2-to 3-day alloxan-diabetic rabbits, 20 the content of arginine in freshly isolated diabetic rat aorta is reduced. 127 If arginine content is in fact diminished in various vascular tissue in diabetes, then replacement therapy should improve NO-mediated relaxation. One study showed that L-arginine partially improved, albeit modestly, basal and agonist-stimulated cGMP in diabetic glomeruli. 154 Incubation in vitro with L-arginine but not D-arginine augments relaxation to acetylcholine but not to nitroglycerin in both streptozotocin 138, 174 and BB diabetic 180 rat aorta. The fact that L-arginine supplementation increased NOS inhibitor-sensitive, acetylcholine-stimulated cGMP production, but not nitroglycerin-stimulated cGMP production, indicates that this effect is specific for augmenting endogenous NO synthesis. 127 In contrast, in one study L-arginine did not improve relaxation to acetylcholine in diabetic rat aorta. 180 It is difficult to reconcile these opposite findings because the duration of disease, species, and artery type were similar. Differences in experimental design and protocols, arginine concentration, and duration of arginine exposure may explain these varied findings. For example, in the study in which arginine had no effect, 181 arginine was given between the second and third challenges to acetylcholine. It would be interesting to know whether multiple challenges in vitro in arginine-free buffers with agents that stimulate NO release further deplete the reservoir of arginine in diabetic tissue such that reversal by L-arginine becomes more resistant.
It has been suggested 99, 182 that the beneficial effects of L-arginine are specific to isolated preparations and due to a theoretical depletion of tissue arginine, since arginine is not normally present in the buffers used for in vitro vascular function studies. This hypothesis is based on an earlier study 183 and is confirmed elsewhere, 184 wherein arginine content decreases rather rapidly in endothelial cells cultured under arginine-free conditions. This possibility cannot yet be excluded for the various in vitro diabetic vascular studies because this has not yet been tested. This hypothesis has been challenged 8 because dysfunction occurs in animals and humans at physiological arginine concentrations.
There are several points that mitigate against the in vitro hypothesis. First, while incubation of porcine aortic endothelial cells in arginine-free media results in depletion of arginine content, this phenomenon apparently does not occur in all types of endothelial cells, even for durations of up to 24 hours of arginine-free conditions. 185 Therefore, it cannot be automatically assumed that arginine depletion in endothelial cells occurs in all intact artery preparations in vitro. Second, if the endothelial dysfunction seen in diabetic arteries tested in vitro is merely due to the absence of arginine in the buffer, it is difficult to reconcile why one does not always observe diminished relaxation in all studies and to all endotheliumdependent vasodilators that also act via NO. Indeed, in the absence of arginine-supplemented buffer, receptor-independent, endothelium-dependent relaxation to the calcium ionophore A23187 in aorta that is normally blocked fully by NOS inhibitors is not diminished in either streptozotocin-induced 137 or genetically prone BB diabetic rats. 33 Third, tissue arginine content in diabetic rat aorta is decreased despite the fact that samples were freshly extracted from animals (ie, without extended incubation in arginine-free media). Fourth, arginine content in isolated coronary endothelial cells of the diabetic BB rat was normal or even slightly elevated, yet these same cells demonstrated defective NO synthesis based on both nitrite release into media and arginine-to-citrulline conversion analysis. 172 These studies also showed that NOS activity in cell homogenates was normal, suggesting impaired arginine utilization under intact cell conditions. Fifth, acetylcholine-stimulated relaxation of diabetic canine coronary arteries was decreased in vivo but not in vitro, 107 and addition of L-arginine to diabetic canine coronary arteries in vitro did not enhance the diminished acetylcholine-stimulated cGMP production. 107 In contrast, in other studies, intracoronary infusion of L-arginine infusion in diabetic dog hearts improved endothelium-dependent relaxation, 20 and in situ application of L-arginine improved nerve blood flow in the rat. 186 These observations would argue against effects of L-arginine that are unique to the in vitro studies and unique to the rat model. Interestingly, effects in the diabetic dog in vivo occurred despite normal plasma arginine concentrations, suggesting that static plasma arginine levels need not be reduced for there to be improvement in endothelial function by L-arginine administration. Why this occurs is unknown. One possibility is that arginine transport might be reduced directly by elevated glycated proteins in the blood. 187 There are reports that appear not to support the concept of defects in L-arginine utilization. In one case, topical application of L-arginine apparently did not improve relaxation in basilar artery of streptozotocin-induced diabetic rats, 188 in cheek pouch microcirculation of diabetic hamsters, 189 or in mesenteric artery of BB diabetic rats. 34 Additional information is needed to determine with total certainty whether these studies reflect important regional differences in the beneficial action of L-arginine on reversal of diabetic endothelial dysfunction because of differences in arginine concentration, duration of exposure, location of application, and duration of disease (see "Discussion") and the potential for crossover effects due to multiple agonist challenges in the same preparation in at least two of these studies. 34, 189 In addition, the ineffectiveness of L-arginine in mesenteric arteries of BB rats is inconclusive, since a short incubation period was used as well as a concentration (ie, 10 mol/L) that is 20 times lower than the physiological concentration of arginine in rat plasma and 10 times lower than the K m of arginine transport into endothelial cells. 129 Furthermore, the potential of masking by crossover effects due to multiple agonist administration has not been excluded in these studies.
One should not discount the possibility that progressive changes in pathology may make endothelial dysfunction resistant to modification by L-arginine administration. Indeed, arginine has been shown to be beneficial in short-term 190 but not long-term atherosclerosis. 191 Indeed, L-arginine administration in vitro restores endothelium-dependent relaxation after 8 weeks of diabetes but not after 12 weeks of diabetes in aorta of Lewis-strain diabetic rats. 174 It may be noteworthy to consider the possibility that the negative results of topical application of L-arginine in situ in basilar arteries were observed in animals of 12-week disease duration. Currently, there is no information whether duration of disease alters arginine transport kinetics.
Transport kinetics into vascular smooth muscle cells during topical application of arginine in diabetic arteries is another consideration. This initial uptake must be sufficient to optimize intracellular arginine at a concentration adequate to facilitate subsequent uptake by diabetic endothelium. It was presumed that the concentration of arginine that failed to augment relaxation in diabetic rat basilar artery and hamster cheek pouch microcirculation was adequate on the basis of improved relaxation in basilar artery of hypertensive rats 192 and in cheek pouch of cardiomyopathic hamsters 193 using a similar arginine concentration. It is possible that the concentration and time of exposure and alterations in transport into vascular smooth muscle are complications that need to be considered for diabetic tissue. Indeed, in studies conducted within the same species, 194 the K m for transport into smooth muscle cells is much lower (ie, 25 mol/L) compared with that for endothelial cells (ie, Ϸ100 mol/L). Furthermore, the maximum capacity for arginine transport is much lower for smooth muscle compared with endothelial cells. These effects might limit the amount of arginine transported by smooth muscle cells and subsequently delivered to endothelial cells to improve NO synthesis in topical application protocols.
Alternatively, protein kinase C (PKC) is known to be increased in diabetic rat aorta and heart 195, 196 and in vascular smooth muscle cells exposed to elevated glucose concentrations. 196 Furthermore, PKC inhibitors normalize relaxation in the cerebral arteries of diabetic or hyperglycemic rats. 80, 197 PKC activation is known to markedly reduce arginine transport in normal rat vascular smooth muscle cells. 198 Thus, these alternative hypotheses should be addressed before final conclusions can be drawn regarding regional differences in efficacy of arginine to restore endothelial function.
The efficacy of arginine in diabetic kidney seems less in doubt. The hyperfiltration and proteinuria produced in shortterm diabetes in rats was prevented by dietary arginine supplementation. 158 Paradoxically, this was associated with a reversal of the enhanced urinary excretion of nitrate/nitrite and cGMP, suggesting that dietary arginine represses the augmented renal production of NO at early stages of the disease. In 2-month diabetic rats, arginine modestly improved the decreased basal and agonist-stimulated cGMP in glomeruli but not to control levels (cGMP). Interestingly, with slightly longer disease duration, arginine failed to alter the decreased basal and agonist-stimulated NO as measured by the NO electrode, 199 which is in agreement with temporal studies in diabetic rat aorta. 174 Conclusion. There is increasing evidence both in vivo and in vitro that arginine can improve endothelial dysfunction and NO production in diabetes. Because of certain methodological considerations, additional studies are warranted to determine whether there are important regional differences in vascular response to arginine and whether arginine will be efficacious at various stages of the disease.
Effects of Arginine on NO in Human Diabetes
The possibility that NO deficits occur in clinical diabetes arises from a report showing that arginine increases plasma nitrate/nitrite levels in diabetic patients. 200 Unfortunately, the effects of arginine in control patients was not evaluated. In one study, arginine increased nitrates and exhaled NO by nearly equivalent degrees in control and IDDM patients. 163 The effects of arginine administration in vivo must be interpreted with caution because arginine also increases insulin secretion 201 and the arginine stimulus might be altered by disease. 202 Insulin is reported to cause dilation via stimulation of NO production, [203] [204] [205] although one recent report shows that insulin can produce dilation in the presence of an NOS inhibitor or can be blocked by adenosine receptor antagonists or K ATP -sensitive channel blockers. 206 To circumvent this limitation, one study in patients with uncomplicated IDDM revealed that arginine treatment augmented plasma cGMP levels and L-citrulline levels to a similar extent in both control and IDDM patients. 178 This is consistent with data showing that arginine supplementation improves endothelium-dependent relaxation in NIDDM. 207 In contrast, high concentrations of L-arginine had no effect in IDDM patients. 208 Arginine has also been shown in NIDDM patients but not healthy controls to enhance insulin-mediated dilation. 209 Conclusion. While positive results indicate that arginine may reverse NO deficits in humans, additional studies are required to confirm or refute these initial findings.
Are Effects of Arginine NO/cGMP-Dependent?
It has been widely assumed that the L-arginine-induced improvement in endothelium-dependent relaxation in various other models of vascular disease reflects enhanced NO/cGMP production. The fallacy of this assumption remains to be rigorously tested in diabetic models, since NO can elicit cGMP-independent effects in some tissue. For example, L-arginine augmented endothelium-dependent relaxation in hypertensive arteries via an NO-independent pathway involving cyclooxygenase-derived reactive oxygen. 210 Furthermore, there are studies that show that arginine analogues which inhibit NOS also alter prostanoid synthesis 211 and K ATPmediated relaxation. 212 Thus, it is possible that arginine supplementation might improve relaxation in diabetic arteries via alternative NO-independent pathways.
In diabetic rat aorta, the improvement in relaxation to acetylcholine by L-arginine could be elicited despite coadministration of either TEA, indomethacin, or catalase. 127 This suggests that enhanced K ϩ channel activity, vasodilator prostaglandins, and H 2 O 2 cannot account for the beneficial effects of L-arginine. More recent studies using glibenclamide suggest that L-arginine also does not improve relaxation via enhanced K ATP -mediated relaxation (G.M.P., unpublished observations, 1997). It is not possible to conclude that similar results will be obtained in other arteries and species, since a comprehensive analysis has not been forthcoming. We do note that the beneficial effects of L-arginine in diabetic canine coronaries occurred despite the fact that all animals were treated with aspirin to inhibit cyclooxgenase activity. 20 In diabetic canine coronary arteries and in diabetic rat aorta, restoration of endothelial function by L-arginine cannot be accounted for by altered prostacyclin production or enhanced K ϩ channel activity. Combined with the data showing augmented cGMP generation, this suggests that the effects of arginine in diabetes are specific for enhanced NO activity.
Effects of Arginine on Endothelial Dysfunction Produced by Elevated Glucose Concentration In Vitro or Hyperglycemia In Vivo
One study noted that flow reduction in normal isolated guinea pig hearts resulted in vasoconstriction that was reversed by L-arginine. 213 In contrast, the acute vasodilation produced by flow reduction in the presence of 44 mmol/L D-glucose was augmented by L-arginine. This suggests that arginine may play an important role in autoregulation under high glucose conditions.
In another study, incubation of normal rat mesenteric arteries with elevated glucose concentrations in vitro caused impaired relaxation to acetylcholine. 79 Addition of 0.1 mmol/L L-arginine abrogated the effect of 20 mmol/L glucose and significantly reduced the detrimental effects of 45 mmol/L glucose. Another study showed that glucoseinduced decrease in Na ϩ ,K ϩ -ATPase of normal rabbit aorta was also prevented by coincubation with L-arginine. 214 The direct effects of glucose have also been examined in hyperglycemic clamp experiments in leg blood flow of healthy subjects. 76 The decreased blood flow observed after 60 and 90 minutes of hyperglycemia was completely reversed by L-arginine. The fact that neither D-arginine or L-lysine was effective illustrates the selectivity and specificity for the L-arginine action.
Conclusion. Arginine appears to provide protection from alterations in vascular function caused by elevated glucose concentration. The mechanism of this protection is still unknown.
Potential Actions of Chronic Arginine Treatment on Endothelial Function
In addition to potential action on insulin release, chronic arginine administration may provide multiple benefits to ameliorate diabetes-induced endothelial dysfunction for other reasons. Arginine administration reduces lipid peroxide levels in diabetic patients. 215 Arginine inhibits lipid peroxidation in vitro and has been reported to be a direct scavenger of superoxide anions. 216 Other studies do not support a direct scavenger action for arginine. 217 Alternatively, L-arginine might enhance relaxation by increasing NO release, which in turn scavenges enhanced rates of superoxide anion production that are elevated in diabetic arteries. 33, 114, 135 L-Arginine also reduces collagen accumulation in diabetic mice 218, 219 and in basement membrane thickening 220 and advanced stage glycosylation end products (AGEs). 220, 221 This presumably happens because protein cross-linking involves lysine-like residues that may be competed for by exogenous arginine. Indeed, L-arginine can directly inhibit AGE product formation initiated in vitro. 221 Because AGEs are believed to quench NO, 70 arginine administration might be of benefit to improve endothelium-dependent relaxation by preventing AGE-mediated quenching of NO-dependent relaxation.
The observation that short-term oral administration of arginine restores endothelial dysfunction via NO 151 suggests that it is not obligatory that arginine alter basement membrane defects or AGE products to provide this protection. Certainly, glycosylated hemoglobin is not altered by this intervention, and neither are plasma glucose levels. 151 This suggests that short-term administration of oral arginine may produce benefits independent of glycemic control, insulin secretion, and protein glycation. Perhaps this results from replenishment of diminished arginine stores in diabetic vascular tissue, as has been recently demonstrated, 127 and/or from an increase in the scavenging of superoxide anion radicals due to enhanced NO production.
Conclusion. On the basis of the present experimental evidence, there are several potential pathways by which dietary arginine supplementation in vivo might benefit the diabetic endothelium. This suggests that experimentation using this modality of intervention may be an area of investigation in the prevention or improvement of vascular endothelial dysfunction in diabetes mellitus.
